{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:57:18Z","timestamp":1794283038312,"version":"4.9.0"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"5","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"n\/a"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,24]]},"abstract":"<jats:p>Exatecan (Exa) is a very potent inhibitor of topoisomerase I and anticancer agent. It has been intensively studied as a single agent, a large macromolecular conjugate and as the payload component of antigen-dependent antibody\u2013drug conjugates. The current work describes an antigen-independent conjugate of Exa with polyethylene glycol (PEG) that slowly releases free Exa. Exa was conjugated to a 4-arm 40 kDa PEG through a \u03b2-eliminative cleavable linker. Pharmacokinetic studies in mice showed that the conjugate has an apparent circulating half-life of 12 hours, which reflects a composite of both the rate of renal elimination (half-life \u223c18 hours) and release of Exa (half-life \u223c40 hours). Remarkably, a single low dose of 10 \u03bcmol\/kg PEG-Exa\u2014only approximately 0.2 \u03bcmol\/mouse\u2014caused complete suppression of tumor growth of BRCA1-deficient MX-1 xenografts lasting over 40 days. A single low dose of 2.5 \u03bcmol\/kg PEG-Exa administered with low but efficacious doses of the PARP inhibitor talazoparib showed strong synergy and caused significant tumor regression. Furthermore, the same low, single dose of PEG-Exa administered with the ATR inhibitor VX970 at doses of the DNA damage response inhibitor that do not affect tumor growth show high tumor regression, strong synergy, and synthetic lethality.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A circulating conjugate that slowly releases Exa is described. It is efficacious after a single dose and synergistic with ATR and PARP inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0517","type":"journal-article","created":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T09:59:26Z","timestamp":1682589566000},"page":"908-916","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5800-0391","authenticated-orcid":true,"given":"Shaun D.","family":"Fontaine","sequence":"first","affiliation":[{"name":"1ProLynx, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-2350","authenticated-orcid":true,"given":"Christopher W.","family":"Carreras","sequence":"additional","affiliation":[{"name":"1ProLynx, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1031-8375","authenticated-orcid":true,"given":"Ralph R.","family":"Reid","sequence":"additional","affiliation":[{"name":"1ProLynx, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5366-9109","authenticated-orcid":true,"given":"Gary W.","family":"Ashley","sequence":"additional","affiliation":[{"name":"1ProLynx, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3790-0673","authenticated-orcid":true,"given":"Daniel V.","family":"Santi","sequence":"additional","affiliation":[{"name":"1ProLynx, San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"2023052414070758900_bib1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"2023052414070758900_bib2","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1021\/cr900097c","article-title":"DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition","volume":"109","author":"Pommier","year":"2009","journal-title":"Chem Rev"},{"key":"2023052414070758900_bib3","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023052414070758900_bib4","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-021-01476-w","article-title":"A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers","volume":"125","author":"Zhang","year":"2021","journal-title":"Br J Cancer"},{"key":"2023052414070758900_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","article-title":"TOP1-DNA trapping by exatecan and combination therapy with ATR inhibitor","volume":"21","author":"Jo","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2023052414070758900_bib6","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-19-0419","article-title":"The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination-deficient and schlafen 11-positive cancer cells and synergize with olaparib","volume":"25","author":"Marzi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2023052414070758900_bib7","doi-asserted-by":"crossref","first-page":"eaax2625","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci Transl Med"},{"key":"2023052414070758900_bib8","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2023052414070758900_bib9","first-page":"2134","article-title":"Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia","volume":"8","author":"Giles","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2023052414070758900_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1385\/1-59259-866-8:317","article-title":"Preclinical and clinical development of exatecan (DX-8951f)","volume-title":"Camptothecins in cancer therapy","author":"Rowinsky","year":"2005"},{"key":"2023052414070758900_bib11","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1200\/JCO.2006.07.0201","article-title":"Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer","volume":"24","author":"Abou-Alfa","year":"2006","journal-title":"J Clin Oncol"},{"key":"2023052414070758900_bib12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/annonc\/mdg243","article-title":"Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies","volume":"14","author":"Braybrooke","year":"2003","journal-title":"Ann Oncol"},{"key":"2023052414070758900_bib13","doi-asserted-by":"crossref","first-page":"100204","DOI":"10.1016\/j.esmoop.2021.100204","article-title":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","volume":"6","author":"Adams","year":"2021","journal-title":"ESMO Open"},{"key":"2023052414070758900_bib14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1349-7006.2004.tb03199.x","article-title":"DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models","volume":"95","author":"Kumazawa","year":"2004","journal-title":"Cancer Sci"},{"key":"2023052414070758900_bib15","first-page":"374","article-title":"Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice","volume":"59","author":"Masubuchi","year":"2004","journal-title":"Pharmazie"},{"key":"2023052414070758900_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1158\/1078-0432.703.11.2","article-title":"Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors","volume":"11","author":"Soepenberg","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2023052414070758900_bib17","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1248\/bpb.30.2365","article-title":"Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors","volume":"30","author":"Shiose","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"2023052414070758900_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10637-005-1442-2","article-title":"DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors","volume":"23","author":"Wente","year":"2005","journal-title":"Invest New Drugs"},{"key":"2023052414070758900_bib19","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1073\/pnas.1117147109","article-title":"Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates","volume":"109","author":"Santi","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023052414070758900_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1158\/1535-7163.MCT-19-0709","article-title":"PET imaging of the EPR effect in tumor xenografts using small 15 nm diameter polyethylene glycols labeled with zirconium-89","volume":"19","author":"Beckford Vera","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2023052414070758900_bib21","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.nano.2015.07.015","article-title":"Design considerations for nanotherapeutics in oncology","volume":"11","author":"Stylianopoulos","year":"2015","journal-title":"Nanomedicine"},{"key":"2023052414070758900_bib22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00280-019-03903-5","article-title":"Species-specific optimization of PEG\u223cSN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft","volume":"84","author":"Fontaine","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023052414070758900_bib23","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1021\/jm401644v","article-title":"Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation","volume":"57","author":"Santi","year":"2014","journal-title":"J Med Chem"},{"key":"2023052414070758900_bib24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/acs.bioconjchem.1c00075","article-title":"Attenuation of the reaction of michael acceptors with biologically important nucleophiles","volume":"32","author":"Hearn","year":"2021","journal-title":"Bioconjug Chem"},{"key":"2023052414070758900_bib25","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/dmd.119.087023","article-title":"Exposure-efficacy analysis of antibody-drug conjugates delivering an excessive level of payload to tissues","volume":"47","author":"Zhang","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"2023052414070758900_bib26","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002800050807","article-title":"Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice","volume":"42","author":"Kumazawa","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023052414070758900_bib27","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1349-7006.1995.tb02468.x","article-title":"A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo","volume":"86","author":"Mitsui","year":"1995","journal-title":"Jpn J Cancer Res"},{"key":"2023052414070758900_bib28","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/1535-7163.MCT-22-0217","article-title":"PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors","volume":"21","author":"Thomas","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"2023052414070758900_bib29","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"2023052414070758900_bib30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0006-2952(02)01297-2","article-title":"The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer","volume":"64","author":"van Hattum","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"2023052414070758900_bib31","first-page":"6365","article-title":"Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells","volume":"49","author":"Holm","year":"1989","journal-title":"Cancer Res"},{"key":"2023052414070758900_bib32","first-page":"5749","article-title":"Modeling of the time-dependency of in vitro drug cytotoxicity and resistance","volume":"58","author":"Levasseur","year":"1998","journal-title":"Cancer Res"},{"key":"2023052414070758900_bib33","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1158\/0008-5472.CAN-13-3369","article-title":"ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses","volume":"74","author":"Josse","year":"2014","journal-title":"Cancer Res"},{"key":"2023052414070758900_bib34","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","article-title":"Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress","volume":"39","author":"Thomas","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0517\/3326852\/crc-22-0517.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/5\/908\/3333717\/crc-22-0517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/5\/908\/3333717\/crc-22-0517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T10:07:51Z","timestamp":1684922871000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/5\/908\/726716\/A-Very-Long-acting-Exatecan-and-Its-Synergism-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,24]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0517","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6620331.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144668.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144674.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144680.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144659.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709778","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144671.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144671","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709784","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144677.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144656","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144668","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144656.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6620331","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144674","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144686","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144662.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144665.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6620331.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144680","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709787","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709775","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144665","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709781","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144677","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144686.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709775.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144683","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144683.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709778.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23144659","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709787.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709784.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22709781.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}